ea0090rc6.4 | Rapid Communications 6: Endocrine-related Cancer | ECE2023
Taya Marwa
, Merenbakh-Lamin Keren
, Honig Zohar
, Wolf Ido
, Rubinek Tami
Resistance to endocrine treatment develops with time in virtually all patients with metastatic breast cancer (BC), and eventually most of them are treated with chemotheray. Our group and others discovered a group of mutations in the ligand binding domain (LBD) of the estrogen receptor (ER), that are the direct cause of resistance in ~40% of the patients. The most common mutations are Y537S and D538G ER. Clinical data indicate an association between those ER mutations worse pro...